Whereas the recent primary analysis of the double-blind placebo-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial showed that the addition of the anti-PD-L1 antibody (atezolizumab) did not significantly improve the clinical outcome (12), early analysis of the MEDIOLA phase II study adding the PD-L1 inhibitor (durvalumab) and the angiogenesis inhibitor (bevacizumab) to a PARPi (olaparib) was promising, with an objective response rate >90% for a specific patient group with platinum-sensitive relapsed ovarian cancer harboring germline BRCA mutations (11). Here, CD274 is linked to ovarian carcinoma.